10 results
The primary efficacy variable is the change in PV from baseline as assessed by 3 D ultrasonography after 78 weeks of double-blind treatment with OM 20-40 mg daily compared to ATE 50-100 mg daily.Secondary efficacy variables:Change from baseline PV…
Determinination of the added effects of dietary sodium restriction or diuretic use to antihypertensive and antialbuminuric therapy.
primary aim of the study To investigate the efficacy of PEP-223/CoVaccine HT in decreasing serum testosterone levels to below castrate levels, i.e. to < 2 nmol/l, within 8 weeks after the last of three injectionssecondary aims of the studyTo…
The aim of our study is to find out if and if so to what extent the acute blood pressure lowering response to ACE-inhibition depends on the variation in the ACE-phenotype. If the blood pressure response depends on ACE acitivity, measurement of ACE-…
To compare the effect of amiloride on lithium-induced Nephrogenic Diabetes Insipidus with the effect of hydrochlorothiazide, measured as urine volume and maximal urine osmolality.
To demonstrate whether hydrochlorothiazide or metformin can diminish aquaresis in patients with ADPKD who are treated with tolvaptan as measured by 24-hour urine volume.
To examine the impact of medication induced systolic BP (SBP) reductions >=10 mmHg, while reaching a treatment target of <=140 mmHg, on cerebral blood flow (CBF) in frail elderly with untreated or uncontrolled systolic hypertension at…
Primary:To compare the efficacy of BM in combination with BOR/DEX with that of daratumumab in combination with BOR/DEX in participants with RRMMSecondary:Other efficacy outcomes. Safety and tolerability. PK. Anti-drug antibodies. Questionnaires (…
To evaluate the efficacy of blmf in patients with relapsed or refractory AL amyloidosis.
DOSE EXPLORATION:Primary:To determine the safety and tolerability of GSK2857916 in combination with other anti-cancer treatments (in each sub-study), and to establish the recommended Phase 2 dose for each sub-study combination treatment.Secondary:…